15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 15 firms covering Ideaya Biosciences Inc, 14 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $35.00 to $79.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $53.00 sits 47% above the current $36.15. The rating mix has stayed broadly stable, with Buy-side ratings easing from 15 to 14 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.05 next quarter toward $-3.64 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS15 ratings
Moderate Buy
Strong Buy00%
Buy1493%
Hold17%
Sell00%
Strong Sell00%
Based on 15 analysts giving stock ratings to Ideaya Biosciences Inc.
As of Jul, 14 of 15 firms rate IDYA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
IDYA EPS & revenue forecast
EPS · NEXT QUARTER
$-1.05
Range $-1.26 – $-0.72 · 13 analysts · -179% YoY
Next period, 13 analysts expect Ideaya Biosciences Inc to earn $-1.05 a share (range $-1.26 – $-0.72), versus $1.33 a year earlier. Full-year consensus is $-4.29, growing to $-3.64 the year after.
REVENUE · NEXT QUARTER
$8.6M
Range $0 – $50.0M · 13 analysts · -96% YoY
Revenue is expected to reach $8.6M (range $0 – $50.0M), -95.9% year-over-year. Full-year consensus is $34.1M, rising to $114.6M next year.
Top analysts covering Ideaya Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IDYA.
#1
Silvan Tuerkcan
JMP Securities · Rank #29
Buy
$45.00+24.5% to target
Overall win rate
50%
+ Follow
#2
Anupam Rama
JP Morgan · Rank #62
Buy
$66.00+82.6% to target
Overall win rate
46%
+ Follow
#3
Leonid Timashev
RBC Capital · Rank #69
Buy
$48.00+32.8% to target
Overall win rate
42%
+ Follow
#4
Yigal Nochomovitz
Citigroup · Rank #131
Buy
$65.00+79.8% to target
Overall win rate
43%
+ Follow
#5
Andrew Berens
Leerink Partners · Rank #167
Hold
$33.00-8.7% to target
Overall win rate
50%
+ Follow
IDYA stock forecast FAQ
What is IDYA's average 12-month price target?+
The 14 analysts with a live target average $53.00 for Ideaya Biosciences Inc over the next 12 months, ranging from a $79.00 high to a $35.00 low.
Is IDYA stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 15 analyst ratings, 14 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for IDYA?+
The Street-high target is $79.00 (JP Morgan), and the Street-low is $35.00 (Goldman Sachs). The average of all 14 active targets is $53.00.
How many Wall Street analysts cover IDYA?+
15 analysts have an active rating on Ideaya Biosciences Inc, and 14 firms carry a live 12-month price target.
Who is the most accurate analyst covering IDYA?+
Among analysts who currently cover IDYA, Silvan Tuerkcan of JMP Securities has the strongest overall Quantellect track record (Rank #29). Their current call is Buy with a $45.00 target.
What is Ideaya Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is $-1.05 per share (range $-1.26 – $-0.72) across 13 analysts. Full-year EPS is projected at $-4.29, rising to $-3.64 the following year.
How much revenue is Ideaya Biosciences Inc expected to report next quarter?+
Consensus revenue is $8.6M (range $0 – $50.0M). Full-year revenue is projected at $34.1M, growing to $114.6M next year.
Have analysts been upgrading or downgrading IDYA lately?+
As of Jul, 14 of 15 firms rate IDYA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IDYA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
